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Summary Previously we described the clinical aspects of a phase I study of prolonged continuous infusion of low-dose recombinant interleukin-2 (rIL-2). In the present paper we report several immunological effects in 13
patients with melanoma and renal cell cancer treated on an out-patient basis with rIL-2 for uninterrupted
periods ranging from 5 to 18 weeks. Groups of three patients were treated at following dose levels 0.18, 0.6,
1.8 or 6 x 106 IU m-2 24 h-' and one patient was treated with 3 x 106 IUm2 24 h-'. Prolonged rIL-2
treatment resulted in a dose-dependent and sustained increase in the percentage and absolute number of
(CD56+, CD8dim) natural killer cells. Within this population a preferential increase in the CD56bnght cells with
low expression of CD16 was observed. The CD27 antigen was also upregulated in the CD56bnigltCD16 dim
population. This increase of NK cells was accompanied by an enhancement of the cytotoxic capacity of the
peripheral lymphocytes. No consistent signs of T cell activation or expansion were noted.
The lymphokine interleukin-2 (IL-2) was originally described
as a growth factor for T lymphocytes (Morgan et al., 1976).
Preclinical studies demonstrated that IL-2 also exerts pro-
moting effects on natural killer (NK) cells (Henny et al.,
1981), lymphokine activated killer (LAK) cells (Lotze et al.,
1981; Grimm et al., 1982), B-lymphocytes (Waldmann et al.,
1984) and monocytes (Malkovsky et al., 1987). The cloning
of the IL-2 gene (Taniguchi et al., 1983) led to production of
Escherichia coli derived non-glycosylated recombinant IL-2
(rIL-2) with biological activity comparable with the glyco-
sylated natural IL-2 molecule (Rosenberg et al., 1984; Liang
et al., 1985). Preclinical and clinical studies have demon-
strated the potential of rIL-2 as an immuno-modulating and
anti-tumour agent. Administration of high-dose rIL-2, either
as bolus injection or as continuous intravenous infusion, may
result in objective anti-tumour responses in up to 25% of
patients with advanced cancer, especially renal cell cancer
and melanoma (Negrier et al., 1989; Rosenberg et al., 1989).
Treatment with rIL-2 may lead to substantial shifts in lym-
phocyte subpopulations, the in vivo generation of cells with
LAK activity, augmentation of NK activity, enhanced anti-
body dependent cellular cytotoxicity (ADCC), and the release
of a variety of other cytokines (Hank et al., 1988; 1990;
Gemlo et al., 1988; Schaafsma et al., 1991). These effects are
related to the dosage and duration of the rIL-2 treatment
(Creekmore et al., 1989; Gambacorti-Passerini et al., 1988;
Hank et al., 1988; Kohler et al., 1989; Lotze et al., 1985;
Sondel et al., 1988; Thompson et al., 1988).
The substantial and cumulative toxicity means that high
dose rIL-2 is usually administered for periods less than a
week. There has been recent interest in prolonged administra-
tion of lower, less toxic doses rIL-2. Data are emerging on
the clinical and immunological effects of prolonged and con-
tinued rIL-2 treatment (Caligiuri et al., 1991; Soiffer et al.,
1992). From 1989 to 1991, we conducted a phase I study of
prolonged continuous intravenous infusion of rIL-2 (Euro-
Cetus) at doses ranging from 0.18 to 9 x 106 IU m-2 24 h-'
in 22 patients with renal cell cancer and melanoma admini-
stered on an out-patient basis. As reported in a previous
paper (Vlasveld et al., 1992) clinical toxicity, consisting of
constitutional symptoms without significant organ dysfunc-
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tion, and eosinophilia occurred at a dose > 1.8 x 106 IU m-2
24 h-'. These features were transient, reaching a peak during the third week of treatment. In this report, we describe some
effects on the immune system in 13 patients treated with
rIL-2 at dose levels ranging from 0.18 to 6 x 106 IUm2
24 h-' for a period of 5 to 18 weeks. The composition of
lymphocyte subpopulations and their activation state were
determined. In addition, lymphocytes were tested in vitro for
their proliferative and cytotoxic capacity.
Materials and methods
Patients and treatment
In this phase I study, low dose rIL-2 was continuously
infused through a central venous access on an out-patient
basis. After reconstitution rIL-2 (EuroCetus, Amsterdam, the
Netherlands) was diluted in 10 ml sterile water containing
2% human serum albumin and infused through a long in-
fusion device by a portable pump.
As shown in Table I four groups of three patients, treated
at the dose levels 0.18 x 106 IU (group I), 0.6 x 106 IU
Table I Treatment schedule
Duration Timepointsfor immunomonitoring (wks)
Dose (weeks) Pre During After
Group I(0.18 x 106 IU m 2 24h-')
pt 1 6 0 3,6 4
pt 2 9 0 3,6,9 2
pt3 8 0 3,6 3
Group II (0.6 x 106IU m2 24 h-')
pt 4 10 0 3,6,9 NA
pt5 8 0 3,6 3
pt 6 5 0 2,4 4
Group III (1.8 x 106 IU m-2 24h-')
pt 7 17 0 3,6,9,17 3
pt 8 9 0 3,6,9 2
pt9 6 0 3,6 NA
Group IV(6 x 106 IU m-2 24 h-')
pt 10 14a 0 3,6,10,12 6
pt 11 18 0 3,6,12,15,18 4
ptl2 7 0 6 4
pt 13 14b 0 1,3,6,9,14 4
aDose escalation from 6 to 9 x 106 IU m-2 24 h-' at week 10. bDose
escalation from 3 to 6 x 106 IU m2 24 h-' at week 7. NA = not
available (lost for follow-up).
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(group II), 1.8 x 106 IU (group III) and 6 x 106IU m-2
24 h-I (group IV), were evaluated for immunological effects.
An additional patient (pt 13) was treated with 3 x 106 IU
ml-2 24 h-'. In this patient the dose was escalated from 3 to
6 x 106 IUm2 24 h-' after 7 weeks. In another patient
(pt 10) of group IV, the dose was escalated from 6 to 9 x
106 IU m-2 24 h-' after 10 weeks of treatment. Of these 13
patients (six male and seven female, mean age 52 (range
40-64) years) eight patients had melanoma and five patients
had renal cell cancer. Pre-treatment consisted of surgery in 10
patients, radiotherapy in three patients, systemic chemo-
therapy (Fotemustine®) in one patient and limb perfusion
with melphalan in another patient. Two patients had no
previous treatment. Supportive treatment consisted of para-
cetamol and metoclopramide when indicated. No non-
steroidal anti-inflammatory drugs or steroids were given.
At the start, at regular intervals during treatment and 2-6
weeks after discontinuation of rIL-2, peripheral blood lym-
phocytes (PBL) were collected in preservative-free heparin
glass tubes (see Table I). Mononuclear cells were isolated by
centrifugation on Ficoll-Hypaque density gradients and cryo-
preserved by controlled rate freezing in 10% DMSO, follow-
ed by storage in liquid nitrogen until testing.
Patient sera were collected in heparinised tubes, separated,
and stored at -20°C until use.
Immunofluorescence
The phenotype of the isolated PBL was determined by in-
direct one colour immunofluorescence. All samples from one
patient were analysed in the same experiment. The following
monoclonal antibodies (mAb) were used: anti-CD45 (CLB-
T200, kindly provided by Drs T.W.J. Huizinga, R.A.W. van
Lier and F. Miedema, Central Laboratory of the Netherlands
Red Cross Blood Transfusion Service (CLB), Amsterdam),
anti-CD2 (CLB-Tl1.1/1, CLB), anti-CD3 (SPV-T3b, Nether-
lands Cancer Institute (NKI), Amsterdam), anti-CD4 (Ortho
Diagnostics), anti-CD8 (Ortho Diagnostics), anti-CD27 (9F4,
CLB-CD27/1, CLB), anti-CD28 (CLB-CD28, CLB), anti-
CD20 (Coulter), anti-CD14 (OKM3, Becton Dickinson),
anti-CD56 (Leul9, Becton Dickinson), anti-CDl6 (CLB-
FcRgranl, CLB or Leullb, Becton Dickinson), anti-CD25
(CLB-IL2R/1, CLB), anti-p75 (TU27, kindly provided by Dr
K. Sugamura, Tohoku University School of Medicine, Sen-
dai, Japan (Takeshita et al., 1989), or Mikpl, kindly pro-
vided by Dr M. Tsudo, Tokyo Metropolitan Institute of
Medical Science, Tokyo, Japan (Tsudo et al., 1989)), anti-
HLA-DR (DK22, Dako), anti-CD38 (ATI, NKI), anti-
CD1 la (NKI-L7, NKI), anti-CD1 la (activation epitope)
(NKI-L16, NKI), anti-CD18 (CLB-LFA1/1, CLB), anti-
CD58 (TS2/9, kindly provided by Dr T.A. Springer, Harvard
Medical School, Boston, USA), anti-CD54 (ICAM-1) (p358,
kindly provided by Dr J.P. Johnson, Institute for Immuno-
logy, Munich, Germany, or F10.2, kindly provided by Dr A.
Bloem, Academic Medical Centre, Utrecht, the Netherlands),
and anti-CD45RO (UCHL-1, Dako). Incubation and wash-
ing was done in PBS with 0.5% w/v BSA and 0.02% w/v
sodium azide. Cells (0.5- 1 x 105 cells in 25IAI) were incubated
with the appropriate dilution of mAb in 96 wells U-bottom
microtiter plates (Costar, Badhoevedorp, the Netherlands)
for 30 min on ice, washed twice, incubated with fluorescein
isothiocyanate (FITC) conjugated F(ab)2 fragments of goat
anti mouse Ig (absorbed with human Ig) (GAM-FITC, Tago,
Burlingame, CA, USA) again for 30 min on ice, and washed
once.
For the determination of the expression of various antigens
on T and NK cells, double staining was performed using
phycoerytrin (PE) labelled anti-CD3 (OKT3 PE, Ortho),
anti-CD56 (Leu 19 PE, Becton Dickinson) or anti-CD16
(Leu 11 PE, Becton Dickinson). Before the addition of the
PE labelled conjugates, the cells were incubated with the
appropriate unlabeled mAb, washed, incubated with GAM-
FITC, washed, and finally incubated with normal mouse
serum. Flow cytometry was carried out on a Becton Dickin-
son FACScan apparatus. Analysis of lymphocyte subpopula-
tions was performed gating the lymphocytes with a window
based on forward and side scatter parameters.
Cell culture
Cell lines used for cytotoxicity assays were cultured in
Dulbecco's modified Minimal Essential Medium (D-MEM,
Gibco, Paisley, Scotland) with 2 mM glutamin, 10% foetal
calf serum (FCS) and 100 U ml-' penicillin and 100pgml-'
kanamycin. Proliferation assays were carried out in Iscove's
modified Dulbecco's medium supplemented with 5% inactiv-
ated, pooled human serum, 100 U ml-' penicillin and 100 jig
ml-' kanamycin.
Cytotoxicity
To limit the effects of inter-assay variation, the PBL taken
before, during and after treatment from one patient were
tested in a single cytotoxicity experiment. This experimental
set-up made it necessary to cryopreserve patients' PBL. Pre-
vious experiments with PBL from healthy donors had shown
that incubation overnight at 37°C is needed to restore the
cytotoxic capacity of cryopreserved cells (unpublished data).
Patients' PBL were incubated overnight in medium alone or
in medium with 600 IU rIL-2 ml1' (EuroCetus) at 37°C in a
humidified atmosphere with 5% CO.
NK activity was defined by the ability of the PBL to lyse
K562 target cells, LAK activity was defined by the ability to
lyse Jiyoye (Burkitt lymphoma) target cells, and ADCC (anti-
body dependent cellular cytotoxicity) activity was defined by
the ability of PBL to lyse Jiyoye target cells in the presence
of R24.3, a rat IgG2b mAb directed against a non-poly-
morphic epitope on HLA class II. The cytotoxic capacities of
PBL in the three assays was also determined after additional
in vitro stimulation with 600 IU rIL-2 ml-' for 18 h and were
defined as NKa, LAKa, ADCCa, respectively.
The target cells K562 and Jiyoye were labelled with 5'Cr by
incubation with Na5' Chromate (specific activity 13-22 GBq
mg-' chromium, Amersham, Buckinghamshire, UK), 6.4 MBq
10-6 cells, for 60-120min at 37°C. After washing, R24.3
mAb (100 igml-') was added to part of the Jiyoye cells.
Target cells were dispensed in 96 well round bottom micro-
titer plates (Sterilin, Hounslow, UK) at a concentration of
103 cells/well and mixed with effector cells at six effector/
target (E/T) ratios between 80:1 and 2.5:1 in triplicate in a
final volume of 2001jI. Plates were centrifuged for 2 min at
1,000 r.p.m. and incubated for 4 h at 37°C in humidified air
with 5% CO2. After incubation, plates were centrifuged
(2 min, 1,000 r.p.m.), 100 jil supernatant was harvested from
each well and the 5'Cr content determined in a Packard
Tricarb Liquid Scintillation Counter (Downers Grove, Ill,
USA). The percentage specific 5'Cr release was calculated
with the formula:
T-S
% specific 5'Cr release=
M-S
x 100%
where T = c.p.m. in test sample, M = maximal releasable
label in 2% Triton-X100, 0.5% SDS, 1% sodium deoxycho-
late, 10 nM EDTA and S = spontaneously released label from
target cells in medium.
The cytotoxic capacity of the patients' PBL was expressed
in Lytic Units (30%) 10-6 effector cells, calculated by the
method described (Pross et al., 1981), where one Lytic Unit is
defined as the number ofeffector cells that produce 30% lysis
of 1,000 target cells.
Proliferation assays
After thawing PBL were cultured in medium alone, or in
medium with 6 IU rIL-2 ml-' (21 pM) or 600 IU rIL-2 ml'
(2.1 nM). At a concentration of 6 IUml1 rIL-2 +70% of
the high affinity (CD25/p75) IL-2 receptor is occupied, with
only minimal or no binding to intermediate affinity (p75) and
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rIL-2 saturates approximately 99%, 70% and 15% of these
receptors respectively.
Isolated PBL were also cultured in medium with anti-
CD28 (1/1000) in order to investigate the proliferative
capacity of activated T cells; proliferation of resting T cells
was induced by incubation in medium with immobilised anti-
CD3 (1/2000) and/or anti-CD28 (1/1000) antibodies for 4
days (Vyth-Dreese et al., 1982; Nijhuis et al., 1990). The cells
were cultured in 96 well round bottom microtiter plates
(Costar) at a concentration of 105 cells/well. After incubation
for 4 days at 37°C in 5% CO2 humidified atmosphere, pro-
liferative responses of the cells were measured by a 4 h pulse
with 14.8 kBq/well of 3H-thymidine (3H-Tdr, New England
Nuclear, Boston, Mass., USA), as previously described
(Vyth-Dreese et al., 1982). The data are expressed as mean
c.p.m. 3H-TdR incorporation of triplicate cultures. Standard
deviation values were less than 10%.
Serum anti IL-2 antibodies and soluble IL-2 receptor
Presence of rIL-2 binding-antibodies in the sera obtained
before and after treatment was studied by Enzyme-Linked
Immunosorbent Assay (ELISA). Flatbottom microtiter plates
(Nunc, Roskilde, Denmark) were coated with rIL-2 (100 fig/
well, 10Itg rIL-2 ml-, 50iLM Na2CO3, pH 9.6) for 18 h at
2-8°C. Plates were preincubated for 45 min at 37°C with
PBS/BSA 4% (100tl/well). A 100 fl of serial dilutions of
control and patient sera were added and the plates were
incubated for 45 min at 37°C. Subsequently plates were
incubated with Rabbit anti-human Ig, conjugated to horse
radish peroxidase (RaHulg-HRP) for 45 min at 37°C, fol-
lowed by O-Phenylene Diamine (OPD) substrate. After
5-15 min the colour reaction was stopped by the addition of
1 N H2SO4, and the extinction read at 492 nm with a Titertek
Multiscan (Flow Laboratories, Herts, UK),
Before, at 3 week intervals, and after treatment with rIL-2,
serum levels of soluble IL-2 receptor were detected by ELISA
(kindly provided by EuroGenetics, Amsterdam, the Nether-
lands), according to the manufacturer's instructions.
Results
0.18 and 0.6 x IP IUm-2 24 h'- (group I andgroup II)
In the six patients treated at the two lowest dose levels (0.18
and 0.6 x 106 IU m-2 24 h-') for a maximum of 9 weeks, we
observed no significant effect on the total lymphocyte count,
the lymphocyte subpopulations, or on the spontaneous cyto-
toxic capacity and proliferative response of the isolated PBL
(Tables II-IV). In pt I of group I and pt 6 of group II, a
small increase in NK and ADCC was noted only after in
vitro stimulation with rIL-2. No LAKa activity was observed.
1.8 x 10J IU m-2 24 h'-I (group III)
Three patients were treated at this dose level for 6, 9 and 17
weeks. In two patients (pts 7 and 9) the absolute number of
CD56+ NK cells more than doubled (Table II), without
changes in the T cell subpopulation. During treatment, the
changes in the cytotoxic capacity of the PBL were variable,
but after in vitro rIL-2 stimulation a pronounced increase in
killing capacity was seen in these patients (Table III).
In patient 9 the percentage and absolute number of cells
expressing the low-affinity IL-2 receptor (p55, CD25) and
intermediate-affinity IL-2 receptor (p75) doubled after 3
weeks of rIL-2 treatment and PBL showed an enhanced
proliferative response to anti-CD3 and/or anti-CD28 mAbs,
but not to rIL-2. In this patient the level of soluble IL-2
receptor in serum at 3 weeks of treatment was dispropor-
tionally increased to that of the patients 7 and 8 (1543 pM vs
736 pM and 400 pM respectively). These data suggested a
possible T cell activation in this patient. To investigate this
further we tested the expression of CD25 and p75 on CD3+
and CD56+ cells of patient 9 at week 3 of treatment by
double staining. The CD25 antigen was expressed on 33% of
the CD3+ cells and there was a weak expression of p75 on
CD3+ cells. These data are compatible with the presence of T
cells with low expression of the high-affinity IL-2 receptor.
Table II The lymphocyte counts in the peripheral blood and the percentage ofexpression ofvarious antigens
on isolated PBL from patients in groups I-IV before and during continuous infusion of rIL-2
Percentage lymphocytes expressing
Lymphocytes CD3 CD4 CD8 CDS6 CD16 CD25 p75
(cells!lll) (%) (%) (
Group I
pt I pre 740 81 61 21 11 15 32 16
max 1660 79 61 24 10 14 26 6
pt 2 pre 2380 75 45 44 27 29 32 5
max 2460 77 46 40 27 31 41 9
pt 3 pre 800 60 37 26 32 29 38
max 750 42 27 28 49 49 32
Group II
pt 4 pre 930 55 36 - 19 17 10 15
max 1060 58 39 26 18 15 8 17
pt 5 pre 2410 75 51 22 21 11 38 20
max 1600 71 57 17 29 20 23 22
pt6 pre 1120 73 44 46 14 17 24 6
max 1240 70 48 53 26 26 24 16
Group III
pt 7 pre 2570 80 44 38 33 10 26 13
max 3100 59 29 36 53 34 17 30
pt 8 pre 4820 77 69 13 18 9 27 13
max 2780 72 62 17 19 12 22 16
pt 9 pre 790 71 53 17 13 20 13 1
max 1470 64 45 25 32 33 26 3
Group IV
pt 10 pre 1340 62 36 37 27 19 20 13
max 6320 15 10 51 76 58 57 77
pt 11 pre 2340 63 47 25 19 18 20 15
max 7380 16 13 51 90 90 53 65
pt 12 pre 950 58 42 26 20 19 10
max 1380 13 10 65 70 50 10 76
pt 13 pre 1800 80 56 30 16 17 50 12
max 1240 55 46 36 36 35 54 31
Max: maximal effect on immunological parameter during rIL-2 treatment. In all but one patient (pt 9) this
effect was maximal at the end of treatment.562 L.T. VLASVELD et al.
Table III Cytotoxic capacity ofthe isolated PBL from patients in groups I-IV against
various targets
Medium Medium+rIL-2
Patient NK ADCC LAK NKa ADCCa LAKa
Group I
pt l pre 1 1 0 22 16 0
max 2 2 0 78 59 4
pt 2 pre 1 0 0 100 41 7
max 1 0 0 66 25 2
pt 3 pre 7 7 0 139 88 42
max 2 10 1 132 114 59
Group II
pt 6 pre 1 1 1 35 6 1
max 1 2 0 165 41 7
Group III
pt 7 pre 1 13 10 124 90 34
max 128 30 11 >1000 207 86
pt8 pre 1 0 0 20 1 0
max 28 2 0 199 23 3
pt 9 pre 5 2 0 108 79 19
max 8 22 0 497 360 53
Group IV
ptlO pre 12 1 0 89 19 12
max 109 21 0 1344 93 52
ptl I pre 4 5 0 39 68 2
max 44 18 0 1578 391 74
ptl2 pre 0 0 3 nt nt nt
max 53 61 0 860 229 4
ptl3 pre 7 8 0 90 44 10
max 8 27 1 314 279 143
Max:maximaleffectonimmunological parameterduringrIL-2treatment. Inallbut one
patient(pt 9) thiseffectwasmaximal attheendofthetreatment. Thecytotoxiccapacity of
thepatients' PBLisexpressed inLyticUnits(30%)/106effectorcells, whereoneLyticUnit
is defined as the number of effector cells that produce 30% lysis of 1000 target cells.
nt = not tested.
Table IV Proliferative capacity of the isolated PBL from patients in groups I-IV
6 rIL-2 600 rIL-2 aCD3+
Patient Medium 21 pM 2.1 nM aCD28 acCD3 aCD28
Group I
pt I pre <1 9 11 1 18 96
max <1 5 10 2 22 91
pt2 pre <1 14 22 11 17 80
max <1 12 14 5 15 76
Group II
pt 6 pre <1 4 7 <1 28 84
max <1 7 8 <1 50 95
Group III
pt 7 pre <1 8 21 2 70 83
max <1 7 23 1 57 94
pt 8 pre <1 2 3 25 3 44
max <1 2 2 23 2 50
pt 9 pre <1 2 4 <1 15 51
max <1 4 6 3 26 89
Group IV
ptlO pre <1 5 12 4 31 132
max <1 4 36 <1 14 129
ptll pre <1 4 10 4 16 85
max <1 12 27 <1 5 80
pt 13 pre <1 5 6 <1 nt nt
max <1 9 7 1 nt nt
Max:maximaleffect onimmunologicalparameterduringrIL-2treatment. Inallbutone
patient (pt 9) this effect was maximal at the end of treatment. aCD28 = anti-CD28
(1/1000) antibody; aCD3 = immobilised CD3 (1/2000) antibody. Data are expressed as
mean c.p.m. x 10-3 from triplicate cultures. nt = not tested.
6x J0'IUm-224h-' (group IV)
Three patients were treated at this dose level for 7, 14 and 18
weeks respectively. Pt 13 was initially treated with 3 x 10' IU
ml-2 24h-' and after 7 weeks the dose was escalated to
6 x 106 IU m-2 24 h-I for another 7 weeks. During the first
weeks of treatment no consistent changes in the lymphocyte
count were observed but after prolonged treatment a sus-
tained increase of the lymphocyte count was noted. In
patient 10 the dose was escalated to 9 x 106 IU m2 24 h-1
after 10 weeks of treatment without evident effect on the
lymphocyte count. In pt 13 no changes in the total lympho-
cyte count were observed, not even after dose escalation.
No changes in the monocyte count occurred in any of the
patients. Since the most striking immunological effects were
noted in these patients, these results will be discussed in
detail.IMMUNOLOGICAL EFFECTS OF CONTINUOUS LOW-DOSE IL-2 563
A: Immunophenotyping oflymphocyte subpopulations
(group IV)
In all three patients treated at the dose level of 6 x 106 IU
m 2 24 h-' there was a pronounced shift within the lympho-
cyte population. The percentage of CD3+ (T) cells decreased
to about one quarter of the baseline levels, while the absolute
number of CD3+ cells remained the same throughout the
treatment (Table II). The percentage and absolute number of
CD56+ cells showed a dramatic and sustained increase dur-
ing treatment. Figure 1 shows a representative graph of the
changes in numbers ofCD3+ and CD56+ lymphocytes. After
treatment the number of CD3+ and CD56+ cells returned to
pre-treatment values. Within the CD56+ cell compartment, a
preferential increase in the percentage of cells with high
expression of CD56 (CD56b'rh') was noted (Figure 2). In
addition there was a preferential increase in the percentage of
cells with low expression of CD16 (CD16dim) and of CD8
(CD8dim) cells (Figure 2).
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Figure 1 Total lymphocyte count and the numbers of (CD3+) T
lymphocytes and (CD56+) natural killer cells in patient 11 treated
with 6 x 106 IU m-2 24 h-' rIL-2.
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The ratio of CD4+ and CD8b"O't lymphocytes did not
change in any of the patients during treatment, while the
relative and absolute number of cells expressing CD25 (a
chain ofthe IL-2 receptor) increased to a variable extent. The
number of cells expressing p75 (p chain of the IL-2 receptor)
substantially increased in all patients during treatment and
correlated closely with the number of CD56+ cells (r=
0.966). Simultaneously, the mean fluorescence of CD38 in-
creased (data not shown).
A close correlation was found between the number of
CD3+ and the number of CD28+, and CD45RO+ cells (data
not shown). No changes in cellular expression of CD27,
CD28 and CD45RO were observed.
After discontinuation of treatment, all parameters returned
to pre-treatment level.
No significant changes in the number of B cells were
noted. The expression of the adhesion molecules CD1la,
CD18, CD58 (LFA-3) and CD54 (ICAM-1) was studied on
the lymphocytes of two patients (pts 10 and 11). CDlla/
CD18 and CD58 were present on essentially all lymphocytes.
There was a tendency to increased expression of CDlla/
CD18 during treatment, whereas no changes were seen in the
expression ofCD58. The activation epitope of LFA-la chain,
detected by the monoclonal antibody NKI-L16, showed no
consistent changes in the total lymphocyte population. The
number of CD54+ lymphocytes, determined on a limited
number of samples, increased during treatment (data not
shown).
In patient 10 the escalation of the dose from 6 to 9 x 106
IU m-2 24 h-' in week 10 had no evident effect on the
lymphocyte populations. Within the lymphocyte population
of patient 13 a relative increase of NK cells was only
observed after the dose escalation to 6 x 106 IU m-2 h-l.
Two colourfluorescence (group IV)
A number of phenotypic markers was also tested by double
staining, in order to discriminate between their expression on
T cells and on NK cells. In patient 10 the week 6, 10 and 12
samples were analysed. In patient 11 double staining was
performed on samples taken before (week 0) and at week 6,
12, 15 and 18 during treatment while in patient 13 samples
taken before (week 0) and at week 9 were available.
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Figure 2 Changes in expression of CD56, CD16 and CD8 on the PBL from patient 10 (above) and patient 11 (below) before
treatment (thin lines) and during treatment at 14 weeks (pt 10) and 12 weeks (pt 11) respectively (thick lines). The figures show a
definite increase in the relative expression of CD56brigh, CD16dim, and CD8dim cells in both patients.
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a Only a small percentage (5%) of the PBL were CD3+
CD56+ throughout rIL-2 treatment. B7 Within the NK cell population significant changes occur-
red after >6 weeks of treatment, consisting of an increase of
CD56b''g't cells in all patients. After >6 weeks of treatment
30-85% of the entire CD56+ cells expressed CD16, 35-80%
expressed CD8, >95% expressed p75 and CD2, virtually no
15 cells expressed CD25, and 30-45% expressed CD27. The
adhesion molecule LFA-1 was present on virtually all CD56+
56
4- cells, and 60-75% expressed CD54 (ICAM-1). There was a
to' IA substantial difference in the level of expression of some of
these antigens among the CD56dim and CD56bfght subpopula-
tions. In comparison with CD56dim cells, CD56brigt cells had a
low expression of CD16, while the expression of CD2, CD27
and CD54 was higher on these cells. Between the two NK
subsets there was no difference in the level of p75 expression.
Only pt 11 had a sufficient number of CD56+ cells before
treatment to perform a reliable double staining. The expres-
I sion of the various antigens on CD56+ cells before and at
weeks 15 of treatment were tested on two occasions. During
treatment the percentage of CD56+ cells expressing CD8
104 increased from 60 to 70%, those expressing p75 rose from 80
to 95%, those expressing CD54 from 35 to 55% and those
58 expressing CD27 from 20 to 45%, while the percentage of
CD56+ expressing CD16 (80-85%), CD2 (80-95%) and
CD25 (<2%) remained similar (mean values of the two
experiments). Representative results are depicted in Figure 3a
illustrating that the CD56bright cells express CD16 at a low
27 level, and CD54, CD2 and CD27 at a high level. To investi-
27 gate the hypothesis that CD27 is primarily expressed on
iCD56bghtCD16dm NK cells, we examined the expression of
IV 14 CD27 on CD16+ cells, and demonstrated that CD27 is indeed primarily expressed on CD16dim cells (Figure 3b).
75 No changes occurred within the T cell population. Before
and during treatment 15-40% of the CD3+ population were
CD8bright, 15-45% expressed CD25. Nearly all T cells ex-
pressed CD27 and CD2, while p75 was virtually negative.
LFA-1 was present on virtually all CD3+ cells, while <30%
of the CD3+ lymphocytes expressed CD54 (tested on a limit-
ed number of samples in pts 10 and 11).
6.
56
-IL B: Cytotoxic capacity (group IV)
Cytotoxicity of PBL without in vitro rIL-2 stimulation In
36 patients 10, 11 and 12 the PBL showed a considerable in-
crease in NK and ADCC activity during treatment (Table
III). The time-course of this increase in cytotoxic capacity is
shown in Figure 4. Cytotoxicity only became apparent in the
samples taken after 6 weeks of treatment and then remained
elevated throughout the entire treatment period.
46 To exclude the possibility that the increased cytotoxic
capacity was solely the result of an increased number of NK
cells, we also expressed the results in Lytic Units 10-6
104 CD56+ cells. After this re-calculation the cytotoxic capacity
of the PBL sampled during treatment remained enhanced.
These results suggest that enhanced activation of NK cells is
induced by the rIL-2 treatment. The limited number of PBL
precluded cytotoxicity assays after T cell depletion.
In patient 13, ADCC was only observed after dose escala-
tion.
Figure 3 a, Double staining of PBL from patient before (left)
and after 15 weeks of rIL-2 treatment (right). Figure 3a shows
that after treatment there is an increase in the percentage of
CD56bnfhg cells. The percentage of CD56+ cells that express p75,
CD54 and CD27 is markedly increased, while the percentage of
CD56+ cells expressing CDl6 and CD2 is not evidently altered.
The graphs also indicate that C56bfght cells have a low level of
CD16, and a high expression of CD54, CD2 and CD27, but not
of p75. b, Demonstrates that CD27 is primarily present on
10!4 CD16dlm cells.
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Figure 4 The cytotoxic capacity of the PBL from three patients (pts 10, 11 and 12) treated at the highest dose level. The PBL were
cultured overnight in medium without rIL-2 and the capacity of the PBL to lyse K562 was determined in a standard 5'Cr release
assay (NK activity). Solid bars represent the cytotoxic capacity of the isolated peripheral blood lymphocytes (PBL), hatched bars
represent the cytotoxic capacity of the isolated PBL after correction for the number of CD56+ natural killer cells (CD56).
Cytotoxic capacity of the PBL after in vitro stimulation with
rIL-2 In the two patients (10 and 11) tested, NKa, LAKa
and ADCCa were enhanced during treatment, while in
patient 13 these cytotoxic activities increased only after dose
escalation (Table III).
C: In vitro proliferation assay (Group IV)
The PBL of two (pts 10 and 11) of the three tested patients
showed an increased response to 600 IU rIL-2ml-', while
one of them (pt 11) even responded to 6 IU rIL-2 ml-'
(Table IV), suggesting the presence of lymphocytes expressing
the high-affinity IL-2 receptor.
No enhanced proliferation was noted upon in vitro stimu-
lation with CD3 and/or CD28 antibodies in any of the
patients. The reduced response to anti-CD3 in patients 10
and 11 may be related to a diminished percentage of T cells
during treatment.
Serum anti IL-2 antibodies andsoluble IL-2 receptor
(groups I-IV)
Before and after treatment no IgG and IgM antibodies
against IL-2 were detected.
The plasma level of the soluble IL-2 receptor (sIL-2R) was
determined on cryopreserved plasma isolated before, at
regular intervals during and after rIL-2 treatment. Before and
after treatment the plasma sIL-2R concentration was below
200 U ml-'. There was a close relationship (r = 0.948)
between the dose and the plasma sIL-2R concentration as
measured after 3 and 6 weeks of rIL-2 treatment. During
further prolonged rIL-2 treatment the plasma sIL-2R tended
to decrease. After dose escalation, no increase in the plasma
sIL-2 was noted. There was no correlation between the
plasma sIL-2R concentration and the absolute number of
CD25+ cells (r = 0.204) or any other immunological para-
meter.
Discussion
In this study we investigated the immuno-modulating effects
of prolonged continuous infusion of EuroCetus rIL-2 and
demonstrated that this mode of administration for a period
of more than 6 weeks may result in a sustained activation of
the immunesystem. We confirm the data from others that
prolonged treatment with rIL-2 results primarily in an in-
creased number and activity of NK cells in a dose-dependent
way (Caligiuri et al., 1991; Soiffer et al., 1992).
The most striking and consistent immunological effects
occurred at a dose 6 x 106 IU m-2 24 h-'. In these patients
we noted a sustained and marked increase of NK cells with
enhanced cytotoxic capacity of the PBL, without alterations
within the T cell subpopulations.
Particularly in the two patients treated for 14 and 18
weeks, a steady time-dependent lymphocytosis occurred with
a 10-20 fold increase in the number of natural killer cells.
Natural killer cells, phenotypically best defined as CD3-
CD56+ lymphocytes, comprise 10-15% of normal resting
blood lymphocytes (Nagler et al., 1989; Lanier et al., 1986;
Robertson et al., 1990b). Based on the cellular co-expression
of CD56 and CD16 (the low affinity Fc receptor for IgG),
several subsets of NK cells can be identified. More than 90%
of resting NK cells express CD56 at a low level with a high
expression of CD16 (CD56dimCD16brghl), and a small subset
of NK cells express CD56 at a high level (CD56bright) with
low or no expression of CD16 (Nagler et al., 1989; Lanier et
al., 1986). This and other studies indicate that rIL-2 treat-
ment leads to a preferential increase in the relative and
absolute number of the CD56brightCD16dim and CD56bright-
CD16- subsets (Ellis et al., 1988; 1989; Soiffer et al., 1992;
Weil-Hillman et al., 1989; Urba et al., 1990).
The shift within the NK subsets has several consequences
for the phenotypic and functional characteristics of the NK
cells. The intermediate affinity IL-2 receptor p75 is expressed
by the majority of resting NK cells (Caligiuri et al., 1990;
Nagler et al., 1989; Ohashi et al., 1989; Tsudo et al., 1986;
Voss et al., 1990) and only a small subpopulation of NK (the
CD56bNight) cells express the high-affinity IL-2 receptor (CD25/
p75) (Caligiuri et al., 1990; Nagler et al., 1990). We and
others (Thompson et al., 1989; Voss et al., 1990; Weil-
Hillman et al., 1990) have demonstrated that the CD25
expression on CD56+ cells remains virtually negative during
prolonged in vivo rIL-2 treatment, suggesting down regula-
tion of the high-affinity IL-2 receptor on the CD56bnrit NK
subset (Voss et al., 1990). Nevertheless, in patient 11 the
appearance of a small subset of NK cells expressing the high
affinity IL-2 receptor is suggested by the fact that the PBL of
this patient displayed an enhanced proliferative response
upon in vitro stimulation with 6 IU ml-' rIL-2 (Weil-Hillman
et al., 1989; 1990).
During rIL-2 treatment we and others observed an increase
of CD56+ cells expressing the adhesion molecule CD54
(ICAM-1) (Triozzi et al., 1992), indicating activation as has
been demonstrated after in vitro stimulation (Robertson et
al., 1990a). We noted that the increase occurred primarily on
the CD56bnigh'CD16dim cells.
Unexpectedly, we found that prolonged rIL-2 treatment
resulted in an increased expression of CD27 on CD56+ cells,
particularly on the CD56bngh'CD16dim population. CD27, init-
ially thought to be a T cell-specific antigen present on the
majority ofT cells, plays a prominent role in T cell activation
(Lier van et al., 1987; Sugita et al., 1991). Very recently it has
been demonstrated that CD27 is also expressed at a low level
on resting NK cells, especially on the CD56bNigh, population
and that the expression is upregulated after in vitro stimula-
tion with rIL-2 (Sugita et al., 1992). Our data confirm that
CD27 is present on a small percentage of resting NK cells
and show that CD27 is upregulated on a subpopulation after
in vivo rIL-2 treatment.
These phenotypic changes, reflecting the presence of an
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activated NK cell population induced by rIL-2 treatment,
were accompanied by an increased natural killer (NK) activ-
ity and antibody dependent cellular cytotoxicity (ADCC),
which was further enhanced after additional in vitro stimula-
tion with rIL-2. Lymphokine activated killer (LAK) activity
measured after in vitro rIL-2 stimulation was also increased
during treatment. Increased cytotoxic capacity of PBL during
rIL-2 treatment has been described by others using freshly
isolated cells (Creekmore et al., 1989; Kohler et al., 1989;
Thompson et al., 1989; Urba et al., 1990). Because we used
cryopreserved lymphocytes in order to test all samples in a
single experiment, no quantitative comparison with our data
can be made.
Since T cell activation, determined by an increase of CD3+
cells expressing CD25 or HLA-DR, has only been observed
after short-term treatment with high-dose rIL-2 (Thompson
et al., 1989; Yoshino et al., 1991), it is not surprising that we
did not find indications for T cell expansion or activation
after prolonged infusion of relatively low dose rIL-2. The
CD4/CD8bMht ratio remained unchanged during treatment
and there was no increased expression of markers associated
with T cell activation, such as CD27 or CD25. One patient
(pt 9), however, treated at 1.8 x 106 IU m 2 24 h'- had subtle
signs of T cell activation after 3 weeks of treatment. A low
expression of the high-affinity IL-2 (CD25/p75) was present
on CD3+ cells, the isolated PBL showed increased prolifera-
tion upon T cell specific stimulation, and the patient had
disproportionally elevated serum soluble IL-2 receptor levels,
which may be indicative for lymphocyte activation (Voss et
al., 1989; Rubin et al., 1990).
The observed pattern of the serum soluble IL-2 receptor
levels in our patients is in agreement with that observed by
others (Bogner et al., 1992; Lissoni et al., 1991: Lotze et al.,
1987; Voss et al., 1989) showing that during prolonged inter-
mittent or continuous rIL-2 treatment, the serum levels grad-
ually increase during the first week(s) followed by a plateau
level or a gradual decline as rIL-2 treatment continues.
Although in vitro studies indicate that soluble IL-2 receptor
may be released upon stimulation of T and B lymphocytes
(Hofmann et al., 1992), the source of sIL-2R in patients
treated with rIL-2 for advanced cancer is obscure. In this
study we confirm that the serum sIL-2R levels are closely
related to the dose of rIL-2 (Bogner et al., 1992). As also
reported by others (Lotze et al., 1987), the serum sIL-2R
level could be correlated with the clinical toxicity observed in
our patients (Vlasveld et al., 1992), which reached a peak
after 3 weeks of treatment followed by a decrease despite
continuation of the rIL-2 treatment.
In the clinical analysis of the present study (Vlasveld et al.,
1992) a short term partial remission was observed in one
patient (pt 8). The immunological effects in this patient were
not different from those observed in non responding patients.
In conclusion, prolonged continuous intravenous adminis-
tration of rIL-2 results in a dose-dependent increase in the
number of NK cells, preferentially of the CD56brightCD16dim
fraction. The NK cells had phenotypical signs of activation
and displayed enhanced functional activity. During treatment
we observed no expansion or activation of T cells. In con-
trast to the observed transient pattern of clinical toxicity and
eosinophilia (Vlasveld et al., 1992), the changes within the
NK population were sustained.
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